Literature DB >> 3288468

Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension.

N N Stanley1, J L Thirkettle, M P Varma, H Larkin, I D Heath.   

Abstract

This randomised, double-blind, crossover study investigated the haemodynamic effects of a beta-blocker (atenolol 50mg) and a calcium antagonist (sustained release nifedipine 20mg) given either separately or in combination in 3 groups of patients with mild to moderate essential hypertension. Each treatment was administered twice daily. The fixed combination given twice daily for 4 weeks produced reductions in blood pressure which lasted for at least 12 hours after administration of the final dose. The control of blood pressure by the combination was superior to that achieved by its individual components. Side effects normally associated with nifedipine therapy were less frequent when it was administered with atenolol. Compliance with treatment was good, but it was best when the drugs were given together rather than separately. A fixed combination of atenolol and nifedipine may prove useful in treating hypertensive patients inadequately controlled on beta-blocker therapy alone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3288468     DOI: 10.2165/00003495-198800354-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  13 in total

1.  To be taken as directed.

Authors:  M S Gatley
Journal:  J R Coll Gen Pract       Date:  1968-07

2.  The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1984-05

3.  Epinephrine-induced hypokalemia: the role of beta adrenoceptors.

Authors:  J L Reid; K F Whyte; A D Struthers
Journal:  Am J Cardiol       Date:  1986-04-25       Impact factor: 2.778

Review 4.  Nifedipine in combination therapy for chronic hypertension. A review.

Authors:  L G Ekelund
Journal:  Am J Med       Date:  1985-10-11       Impact factor: 4.965

5.  Half-strength atenolol-chlorthalidone combination (tenoretic mite) in the treatment of elderly hypertensive patients.

Authors:  R Fogari; A Zoppi
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-07

6.  Long-term therapy of arterial hypertension with nifedipine given alone or in combination with a beta-adrenoceptor blocking agent.

Authors:  S E Husted; H K Nielsen; C K Christensen; O Lederballe Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol.

Authors:  L H Opie; L Jee; D White
Journal:  Am Heart J       Date:  1982-09       Impact factor: 4.749

8.  Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension.

Authors: 
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

9.  Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone.

Authors:  A R Daniels; L H Opie
Journal:  Am J Cardiol       Date:  1986-04-15       Impact factor: 2.778

10.  The effects of cardioselective and non-selective beta-adrenoceptor blockade on the hypokalaemic and cardiovascular responses to adrenomedullary hormones in man.

Authors:  A D Struthers; J L Reid; R Whitesmith; J C Rodger
Journal:  Clin Sci (Lond)       Date:  1983-08       Impact factor: 6.124

View more
  2 in total

Review 1.  Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy?

Authors:  D A Sica
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 2.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.